Home/Pipeline/ALZN002

ALZN002

Alzheimer's Disease

PreclinicalResearch

Key Facts

Indication

Alzheimer's Disease

Phase

Preclinical

Status

Research

Company

Alzamend Neuro

About Alzamend Neuro

Alzamend Neuro is a clinical-stage biotech focused on developing novel therapeutics for Alzheimer's disease, bipolar disorder, MDD, and PTSD. Its strategy leverages two licensed technology platforms: an ionic cocrystal for improved lithium delivery (AL001) and a cell-based immunotherapeutic vaccine for Alzheimer's (ALZN002). Key recent achievements include initiating a Phase II trial for AL001 in bipolar disorder with Massachusetts General Hospital and completing a $5 million private placement. The company operates as a lean, development-focused entity targeting significant unmet needs in large patient populations.

View full company profile

Therapeutic Areas

Alzheimer's Disease Bipolar Disorder Major Depressive Disorder Post-Traumatic Stress Disorder

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	Johnson and Johnson Innovative Medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active
PMN310	ProMIS Neurosciences	Phase 1b	Active - PRECISE-AD trial fully enrolled
Aucuba-001	Aucuba Sciences	Preclinical	Active